Roger S. Lo, MD, PhD

Roger Lo, MD, PhD

Professor, Department of Medicine, Dermatology
Professor, Department of Molecular and Medical Pharmacology
Director, Melanoma Clinic in Dermatology





Institutional Affiliation

UCLA Medical Center, Santa Monica
Ronald Reagan UCLA Medical Center



Medicine, St. Vincent's Medical Center, 2002 - 2003


PhD, Tri-Institutional Program (Cornell University Medical College, Rockefeller University, and Sloan-Kettering Institute), 2002
MD, Cornell University Medical College, 2002


Dermatology, UCLA, 2003 - 2006

Board Certification

Dermatology, American Board of Dermatology, 2007

Contact Information


(310) 917-3376 - General Dermatology Information and Referral
(310) 267-4433 - General Dermatology Prescription Refills
(310) 825-6911 - Dermatology Surgery Clinic Information and Referral
(310) 267-4472 - Dermatology Surgery Clinic Prescription Refills

Scientific Interests

Dr. Roger Lo's laboratory is focused on melanoma research in three thematic areas:

  • Discovering somatically mutated genes in melanoma using exon capture and next-generation sequencing and studying these genes in the pathogenesis of melanoma.
  • Dissecting oncogene co-dependent survival networks in melanoma using V600EB-RAF as a prototypic melanoma oncogene and siRNA library as a discovery tool.
  • Understanding the mechanisms of primary and acquired resistance to targeted therapies (including B-RAF inhibitors) using integrated genomic technologies.

Highlighted Publications

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A,Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 9;27(2):240-56. doi: 10.1016/j.ccell.2014.11.018. Epub 2015 Jan 15.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.